Literature DB >> 7995522

Influence of a steroid receptor DNA-binding domain on transcriptional regulatory functions.

J A Lefstin1, J R Thomas, K R Yamamoto.   

Abstract

We have isolated two independent mutations in the DNA-binding domain of the rat glucocorticoid receptor, P493R and S459A, that implicate DNA binding in the control of attached transcriptional activation domains, either that of the receptor itself or of VP16. The mutants are capable of activating transcription normally, but unlike wild-type receptors, they interfere with particular transcriptional activators in yeast and mammalian cells, and inhibit growth when overexpressed in yeast. The mutant residues reside at positions within the three-dimensional structure of the receptor that could, in principle, transduce structural changes from the DNA-binding surface of the receptor to other functional domains. These findings, together with the salt dependence of specific and nonspecific DNA binding by these receptors, suggest that specific DNA acts as an allosteric effector that directs the functional interaction of the receptor with targets of transcriptional activation and that the P493R and S459A mutants mimic the allosteric effect of specific DNA, allowing the receptor to interact with regulatory targets even in the absence of specific DNA binding.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7995522     DOI: 10.1101/gad.8.23.2842

Source DB:  PubMed          Journal:  Genes Dev        ISSN: 0890-9369            Impact factor:   11.361


  36 in total

1.  Structure of HAP1-PC7 bound to DNA: implications for DNA recognition and allosteric effects of DNA-binding on transcriptional activation.

Authors:  A K Lukens; D A King; R Marmorstein
Journal:  Nucleic Acids Res       Date:  2000-10-15       Impact factor: 16.971

2.  Quantitative characterization of the interaction between purified human estrogen receptor alpha and DNA using fluorescence anisotropy.

Authors:  M Boyer; N Poujol; E Margeat; C A Royer
Journal:  Nucleic Acids Res       Date:  2000-07-01       Impact factor: 16.971

3.  A common motif within the negative regulatory regions of multiple factors inhibits their transcriptional synergy.

Authors:  J A Iñiguez-Lluhí; D Pearce
Journal:  Mol Cell Biol       Date:  2000-08       Impact factor: 4.272

4.  Synergistic activation of the fibroblast growth factor 4 enhancer by Sox2 and Oct-3 depends on protein-protein interactions facilitated by a specific spatial arrangement of factor binding sites.

Authors:  D C Ambrosetti; C Basilico; L Dailey
Journal:  Mol Cell Biol       Date:  1997-11       Impact factor: 4.272

5.  Quantification of ligand-regulated nuclear receptor corepressor and coactivator binding, key interactions determining ligand potency and efficacy for the thyroid hormone receptor.

Authors:  M Jeyakumar; Paul Webb; John D Baxter; Thomas S Scanlan; John A Katzenellenbogen
Journal:  Biochemistry       Date:  2008-06-18       Impact factor: 3.162

Review 6.  Crosstalk in inflammation: the interplay of glucocorticoid receptor-based mechanisms and kinases and phosphatases.

Authors:  Ilse M E Beck; Wim Vanden Berghe; Linda Vermeulen; Keith R Yamamoto; Guy Haegeman; Karolien De Bosscher
Journal:  Endocr Rev       Date:  2009-11-04       Impact factor: 19.871

7.  The glucocorticoid receptor inhibits NFkappaB by interfering with serine-2 phosphorylation of the RNA polymerase II carboxy-terminal domain.

Authors:  R M Nissen; K R Yamamoto
Journal:  Genes Dev       Date:  2000-09-15       Impact factor: 11.361

8.  Intramolecular regulation of MyoD activation domain conformation and function.

Authors:  J Huang; H Weintraub; L Kedes
Journal:  Mol Cell Biol       Date:  1998-09       Impact factor: 4.272

9.  Repression by HoxA7 is mediated by the homeodomain and the modulatory action of its N-terminal-arm residues.

Authors:  C A Schnabel; C Abate-Shen
Journal:  Mol Cell Biol       Date:  1996-06       Impact factor: 4.272

Review 10.  Corticosteroids in the brain. Cellular and molecular actions.

Authors:  M Joëls; E Vreugdenhil
Journal:  Mol Neurobiol       Date:  1998       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.